HomeNew c-Met Inhibitors

New c-Met Inhibitors

Catalog No. Product Name Information
A4000 Amivantamab (Anti-cMet & EGFR) Amivantamab is a fully human bispecific antibody that targets both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It exhibits immune anticancer activity in non-small cell lung cancer (NSCLC). MW :145.88 KD.
E4914 Cabozantinib hydrochloride Cabozantinib hydrochloride(XL184, BMS-907351 hydrochloride) is a potent small-molecule kinase inhibitor of c-MET and VEGFR2 with an IC50 of 1.3 nM, 0.035 nM respectively. It also inhibits RET, KIT, AXL, Tie2 and FLT3 with an IC50's of 5.2 nM, 4.6 nM, 7 nM, 14.3 nM, 11.3nM respectively. It can be promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling.
F1442 HRS Rabbit mAb HGS,HRS
≡ All c-Met Inhibitors